← Back to Search

Immunomodulatory Device

SCD Treatment for Acute Kidney Injury (SCD PED-02 Trial)

N/A
Waitlist Available
Research Sponsored by Children's Hospital Medical Center, Cincinnati
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 28 and day 60 post treatment
Awards & highlights

SCD PED-02 Trial Summary

This trial is examining whether a device that removes inflammation-causing cells from the blood can improve survival for kids with acute kidney injury.

SCD PED-02 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 28 and day 60 post treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 28 and day 60 post treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of SCD-related adverse events (AE)
Number of unanticipated adverse device effects (UADE)
Secondary outcome measures
Hospital Length of Stay
Intensive Care Unit (ICU) Length of Stay
Mortality
+1 more

SCD PED-02 Trial Design

1Treatment groups
Experimental Treatment
Group I: SCD TreatmentExperimental Treatment1 Intervention
Pediatric patients receiving SCD + CRRT for up to 10 days

Find a Location

Who is running the clinical trial?

Children's Hospital Medical Center, CincinnatiLead Sponsor
815 Previous Clinical Trials
6,531,586 Total Patients Enrolled
17 Trials studying Acute Kidney Injury
11,353 Patients Enrolled for Acute Kidney Injury
University of MichiganOTHER
1,795 Previous Clinical Trials
6,373,926 Total Patients Enrolled
11 Trials studying Acute Kidney Injury
12,955 Patients Enrolled for Acute Kidney Injury

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Multi-Center Study of a SCD for Immunomodulatory Dysregulation in Pediatric AKI
Stuart Goldstein, MD 2021. "A Multi-Center Study of a SCD for Immunomodulatory Dysregulation in Pediatric AKI". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04869787.
~1 spots leftby Jul 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top